LLY · 8-K · 20260805PR000077
Products and Technology - Retatrutide
ELI LILLY & Co · 2026-08-05 · Importance 31 · Surprise 42
Lilly reported positive data from three additional Phase 3 retatrutide trials in obesity. The completed clinical data package supports global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain. Lilly plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027. Retatrutide is positioned as a next-generation triple agonist for obesity and related complications.